Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03060759 · ClinicalTrials.gov registry record · NA
Light Therapy as Treatment for Fatigue in Multiple Sclerosis
A NA study of Multiple Sclerosis (Relapsing Remitting), sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT03060759: Completed NA study of Multiple Sclerosis (Relapsing Remitting), sponsored by Massachusetts General Hospital.
NCT03060759 is a NA study of Multiple Sclerosis (Relapsing Remitting) that has completed, run by Massachusetts General Hospital. The registered enrollment target is 35 participants, below the 561-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03060759, a NA study of Multiple Sclerosis (Relapsing Remitting), has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This prospective study will randomize 1:1 people living with multiple sclerosis-associated fatigue to one of two spectra of light therapy. Each participant will be asked to use the light box twice daily at home or at the workplace at preset hours during the day for a total of four weeks. Participants will be asked to record their fatigue on standard measurement scales before, during, and after the use of the light therapy box. The investigators anticipate a reduction in self-reported fatigue following the use of the light box therapy of a particular spectrum of light among people living with multiple sclerosis.
Primary Outcome
Measure of general level of fatigue. Range: 9 to 63. Lower scores indicate less reported fatigue.
Conditions Studied
Interventions
- DEVICE Light Therapy box
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-04-01 |
| Est. Completion | 2019-11-04 |
| Phase | NA |
What the finished NCT03060759 record still lists
NCT03060759 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 561-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Multiple Sclerosis (Relapsing Remitting) appearing as the primary indexed condition, and to 1 intervention - of which Light Therapy box is the first listed.
NCT03060759 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03060759 about?
NCT03060759 is a clinical study titled "Light Therapy as Treatment for Fatigue in Multiple Sclerosis". This prospective study will randomize 1:1 people living with multiple sclerosis-associated fatigue to one of two spectra of light therapy. Each participant will be asked to use the light box twice daily at home or at the workplace at preset hours during the day for a total of four weeks. Participant...
What is the current status of trial NCT03060759?
This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2017-04-01. Estimated completion is 2019-11-04.
What conditions does trial NCT03060759 study?
This clinical trial studies the following conditions: Multiple Sclerosis (Relapsing Remitting).
What interventions are being tested in trial NCT03060759?
The interventions under investigation include: Light Therapy box (DEVICE).
Who is sponsoring clinical trial NCT03060759?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03060759 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis (Relapsing Remitting)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03060759's enrollment target sits among peer trials
35 24th of 29 higher than 6 of 29 other Multiple Sclerosis (Relapsing Remitting) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis (Relapsing Remitting) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis
RECRUITING · NA
-
Intermittent Hypoxia in Persons With Multiple Sclerosis
RECRUITING · NA
-
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
RECRUITING · NA
-
Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS
RECRUITING · NA
-
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
RECRUITING · NA
-
The Synergistic Effects of AIH and FES in Persons With MS
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI